Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide and LNG-IUD for Uterine Preservation in Endometrial Hyperplasia
NCT05829460Phase 2Withdrawn
- Sponsor
- Washington University School of Medicine
- Start
- Mar 2025
- Primary completion
- Apr 2030
- Modality
- Peptides, Recombinant Proteins and Enzymes
01
Overview
A Phase 2 trial of semaglutide in endometrial hyperplasia (EH), sponsored by Washington University School of Medicine. Planned start Mar 2025; status: withdrawn.
02
Drugs
03
Conditions
endometrial hyperplasia (EH)
Beyond the preview
Go deeper on NCT05829460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05829460.